RT Journal Article
T1 Plasma midkine levels in patients with cocaine use disorder during abstinence.
T2 Plasma midkine levels in patients with cocaine use disorder during abstinence.
A1 Pallardo-Fernandez, Iñigo
A1 Garcia-Marchena, Nuria
A1 Rodriguez-Rivera, Carmen
A1 Pavon, Francisco Javier
A1 Gonzalez-Martin, Carmen
A1 Rodriguez de Fonseca, Fernando
A1 Alguacil, Luis F
K1 Cocaine
K1 Cocaine-related disorders
K1 Midkine
AB Preclinical evidence suggests that endogenous midkine could play a key modulatory role on the neurotoxic and addictive effects of different kinds of drugs of abuse, including psychostimulants. However, this hypothesis has not yet been explored in humans. As a first approach to progress in this knowledge, we have comparatively studied plasma midkine levels in 75 patients with cocaine use disorder under abstinence and 26 control subjects matched for sex, age and body mass index. Patients were further segmented into early-abstinent (up to one month of abstinence, n = 30) and late-abstinent (more than one month of abstinence, n = 45). Midkine levels were quantified in plasma samples of all the participants by enzyme-linked immunosorbent assays. Early-abstinent patients exhibited a 60% increase of midkine plasma concentration in comparison with the controls. This elevation tended to normalize upon the progression of abstinence. The results obtained demonstrate that peripheral midkine levels are closely related to cocaine use and are consistent with the idea that this cytokine could play a protective role by limiting the biological activity of psychostimulants.
PB Socidrogalcohol
SN 0214-4840
YR 2022
FD 2022-11-29
LK http://hdl.handle.net/10668/21749
UL http://hdl.handle.net/10668/21749
LA en
LA es
NO Pallardo-Fernández I, García-Marchena N, Rodríguez-Rivera C, Pavón FJ, González-Martín C, Rodríguez de Fonseca F, et al. Plasma midkine levels in patients with cocaine use disorder during abstinence. Adicciones. 2022 Nov 29;34(4):273-278
DS RISalud
RD Apr 29, 2025